CD4 and neoplasm: In further analysis of the infiltration of immune cells, we found that compared with the control group, anlotinib and combination treatment group significantly inhibited the aggregation of CD45+ CD4+ CD25+ FoxP3+ T cells in the tumor tissues (Fig. 6a, b).